Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Approval Alert | Blinatumomab in CD19+ Ph– B-Cell Precursor Acute Lymphoblastic Leukemia
Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
2
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
3
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
4
Debate Round 3: Timing of Treatment Initiation in LR-MDS (Earlier vs Delayed)
5
